Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study
Disease progression on 1 L PARPi maintenance was associated with poorer outcomes after subsequent chemotherapy. Incorporating bevacizumab into 2 L chemotherapy and maintenance was associated with improved survival.
Authors
- Kenichi Harano (ORCID: https://orcid.org/0000-0002-0833-3489)
- Kazuaki Takahashi (ORCID: https://orcid.org/0000-0003-0419-1927)
- Miki Hayakawa
- Nobuaki Matsubara (ORCID: https://orcid.org/0000-0002-9203-4245)
- Toru Mukohara (ORCID: https://orcid.org/0000-0002-8573-418X)
- Misao Fukuda (ORCID: https://orcid.org/0009-0000-7720-3875)
- Saki Tsuchimochi
- Chikako Funasaka (ORCID: https://orcid.org/0000-0003-0585-4884)
- Masashi Wakabayashi (ORCID: https://orcid.org/0009-0001-6368-5671)
- Yoichi Naito (ORCID: https://orcid.org/0000-0002-8490-9064)
- Chihiro Kondoh (ORCID: https://orcid.org/0000-0001-6189-4851)
- Ako Hosono
- Hiromichi Nakajima (ORCID: https://orcid.org/0000-0001-6401-4258)
- Hiroshi Tanabe (ORCID: https://orcid.org/0000-0003-3776-5819)
- Shogo Watanabe (ORCID: https://orcid.org/0000-0002-1700-2892)
- Mao Uematsu
Institutions
- National Cancer Center Hospital East (JP)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1016/j.ygyno.2025.11.008
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00